During the company's second quarter earning's report, GlaxoSmithKline PLC's new CEO Emma Walmsley outlined key issues for the business over the next three years and set out a series of new priorities, putting the group's pharmaceutical unit at the top of her to-fix list ahead of the consumer health and vaccine units.
The new CEO's corporate overhaul contains many more fireworks than analysts and investors had anticipated. GSK's stock price (London Stock Exchange) was trending down by around 1
2Q Numbers At A Glance
- Group sales: £7.3bn
- Operating profit: £2.08bn
- EPS: 27.2p
- Pharmaceutical sales: £4.36bn (cons: £4.31bn)
- Vaccines sales: £1.11bn (cons: £1.08bn)
- Consumer health sales: £1.85bn (cons: £1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?